检索结果-南通市图书馆

IMMUNOSUPPRESSIVE TREATMENT OF CHILDHOOD APLASTIC ANEMIA WITH antithymocyte GLOBULIN (ATG) AND CYCLOSPORIN A (CSA)

Medical Bulletin of Shanghai Jiaotong University 1992年第2期15卷 54-60页

作者：谢晓恬应大明王耀平姚慧玉林梓赵惠君 Department of Pediatrics Xinhua Hospital and Shanghai Institute for Pediatrics Research SSMU Shanghai

This paper described the therapeutic efficacy of immunosuppressive (IS) treatment agents (ATG and CSA) and androgens in the treatment of childhood aplastic anemia (AA). The results showed that the overall curative rate was 52.4% in the ATG therapy group (21 cases) and 58.3% in the CSA therapy group (12 cases) respectively. The effective rate of all patients (SAA and CAA) was 58.1% in the IS group (18/31) and 40.4% in the androgens group (42/104), P>0.05. But, in the childhood patients with SAA, the clinical effective rate was 68.4% in the IS group and 7.9% in the androgens group, P<0.01. The laboratory tests revealed that the majority of the AA patients displalyed abnormal immunological states: inversed CD4/ CD8 ratio and increased IL-2 activity. These abnormal immunological states could be normalized in several patients when clinical response was abtained following IS therapy with ATG and CSA.

关键词： aplastic anemia immanosuppressive treatment antithymocyte globulin cyclosporin A T lymphocytes subsets interleukin-2

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide:results from the Chinese Bone Marrow Transplantation Registry Group(CBMTRG)

引用

Science China(Life Sciences) 2020年第4期63卷 571-581页

作者： Feifei Tang Yajing Xu Huiren Chen Lanping Xu Xiaohui Zhang Yu Wang Qifa Liu Depei Wu Xiaojun Huang Peking University People’s Hospital Peking University Institute of HematologyBeijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044China Xiangya Hospital Central South UniversityChangsha 410008China PLA Army General Hospital Beijing 100700China Nanfang Hospital Southern Medical UniversityGuangzhou 510515China The First Affiliated Hospital of Soochow University Suzhou 215006China Peking-Tsinghua Center for Life Sciences Beijing 100871China

This study compared G-CSF/ATG and PTCy in myeloablative haploidentical hematopoietic stem cell transplantation(haploHSCT)for hematologic malignancies between January 2013 and March 2018 reporting to the Chinese Bone Marrow Transplantation Registry Group(CBMTRG).For each PTCy,G-CSF/ATG subjects(1:4)were selected using the nested case-pair *** total,220 patients including 176 in G-CSF/ATG group and 44 in PTCy group were *** incidences of 30-day neutrophil engraftment(88.6%vs.96.6%,P=0.001),90-day platelet engraftment(84.1%vs.94.2%,P=0.04),the median time to neutrophil engraftment(17 days vs.12 days,P=0.000)and platelet engraftment(22 days vs.17 days,P=0.001)were significantly inferior in PTCy *** incidences of grades 2–4 and 3–4 acute graft-versus-host disease(GVHD),chronic GVHD and severe chronic GVHD were *** G-CSF/ATG and PTCy groups,the 3-year progression-free survival,overall survival,cumulative incidences of nonrelapse mortality and relapse was 74.3%vs.61%(P=0.045),78.3%vs.65.2%(P=0.039),12%vs.27.3%(P=0.008),and 14.9%vs.11.7%(P=0.61),respectively.G-CSF/ATG can achieve better engraftment,PFS and OS,and lower incidence of NRM compared to PTCy in myeloablative haplo-HSCT for hematologic malignancies.